174 related articles for article (PubMed ID: 31882734)
1. Applied Precision Cancer Medicine in Neuro-Oncology.
Taghizadeh H; Müllauer L; Furtner J; Hainfellner JA; Marosi C; Preusser M; Prager GW
Sci Rep; 2019 Dec; 9(1):20139. PubMed ID: 31882734
[TBL] [Abstract][Full Text] [Related]
2. Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H; Müllauer L; Mader R; Prager GW
Hepatol Int; 2020 Mar; 14(2):288-295. PubMed ID: 32100259
[TBL] [Abstract][Full Text] [Related]
3. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
[TBL] [Abstract][Full Text] [Related]
4. Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.
Kieler M; Müllauer L; Koperek O; Bianconi D; Unseld M; Raderer M; Prager GW
Oncology; 2018; 94(5):306-310. PubMed ID: 29444511
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Yang JW; Choi YL
Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
[TBL] [Abstract][Full Text] [Related]
6. Next generation neuro-oncology.
Weller M
Eur J Cancer; 2018 Jun; 96():1-5. PubMed ID: 29656021
[TBL] [Abstract][Full Text] [Related]
7. Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.
Taghizadeh H; Müllauer L; Mader RM; Schindl M; Prager GW
Ther Adv Med Oncol; 2020; 12():1758835920938611. PubMed ID: 32699558
[TBL] [Abstract][Full Text] [Related]
8. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
9. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
10. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
12. Malignant circuits: Novel therapeutic opportunities in neuro-oncology.
Papavassiliou KA; Papavassiliou AG
J Cell Mol Med; 2021 Mar; 25(6):3167-3168. PubMed ID: 33576106
[No Abstract] [Full Text] [Related]
13. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
14. Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.
Linzey JR; Marini BL; Pasternak A; Smith C; Miklja Z; Zhao L; Kumar-Sinha C; Paul A; Harris N; Robertson PL; Hoffman LM; Chinnaiyan A; Mody R; Koschmann C
J Neurooncol; 2018 Mar; 137(1):155-169. PubMed ID: 29235051
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI.
Taghizadeh H; Unseld M; Spalt M; Mader RM; Müllauer L; Fuereder T; Raderer M; Sibilia M; Hoda MA; Aust S; Polterauer S; Lamm W; Bartsch R; Preusser M; A KW; Prager GW
J Pers Med; 2020 Oct; 10(4):. PubMed ID: 33114048
[TBL] [Abstract][Full Text] [Related]
16. The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.
Lin VTG; Yang ES
J Natl Cancer Inst; 2019 Oct; 111(10):1016-1022. PubMed ID: 31165154
[TBL] [Abstract][Full Text] [Related]
17. Enabling Precision Oncology Through Precision Diagnostics.
Brown NA; Elenitoba-Johnson KSJ
Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
[TBL] [Abstract][Full Text] [Related]
18. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
